[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338617-105":59,"doc-detail-338617-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cyfip2-potential-pancreatic-cancer-biomarker-and-immunotherapeutic-target","CYFIP2 - potential pancreatic cancer biomarker and immunotherapeutic target","","Objective: CYFIP2 (Cytoplasmic FMR1-interacting protein 2) shows p53-dependent apoptosis and is linked to poor prognosis in several cancers, but its prognostic value in pancreatic cancer is unclear. This study integrates pan-cancer profiling to clarify CYFIP2’s malignant progression potential and validates its oncogenic relevance in pancreatic cancer. Methods combine TCGA, GTEx, CELL, and GEO with multiple bioinformatics platforms and statistical and functional assays. Results associate CYFIP2 with tumor stage, survival risk, immune-cell infiltration patterns, and distinct mutation/methylation influences. Conclusion: CYFIP2 emerges as a candidate marker and immunotherapy-related target in pancreatic cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cyfip2-potential-pancreatic-cancer-biomarker-and-immunotherapeutic-target/338617/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cyfip2-potential-pancreatic-cancer-biomarker-and-immunotherapeutic-target/338617.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding CYFIP2 in pancreatic cancer?","Question",{"text":112,"@type":113},"The study addresses the uncertainty about whether CYFIP2 has prognostic potential in pancreatic cancer, despite evidence of CYFIP2 involvement in poor prognosis for other cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases and analytical tools are used to study CYFIP2?",{"text":117,"@type":113},"The study uses TCGA, GTEx, CELL, and GEO, analyzing CYFIP2 distribution, expression, survival relationships, immune infiltration correlation, and pathway functions with multiple web-based platforms and R packages such as limma, ggplot2, survminer, survival, and ssGSEA.",{"name":119,"@type":110,"acceptedAnswer":120},"How is CYFIP2 linked to immune infiltration and tumor progression in the results?",{"text":121,"@type":113},"CYFIP2 expression in pancreatic cancer is positively correlated with most immune cells, especially CD8+ T cells, negatively correlated with macrophages M0, and associated with reduced metastatic and invasive ability of pancreatic cancer cells, suggesting a role in immunotherapy strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338617,1790194074,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Research  \nCYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target  \nCong Xiao1 · Xiaojuan Zhang1 · Bobo Hou1 · Ping Wan1 · Zhenjun Cao1 · Xuefeng Rao2  \nReceived: 2 February 2024 / Accepted: 28 November 2024  \n© The Author(s) 2025 OPENPublished online: 30 December 2024  \nAbstract  \nObjective It has been shown that the CYFIP2 (Cytoplasmic FMR1-interacting protein 2) gene is apoptosis p53-dependent and is associated with poor prognosis in malignant tumors such as gastric cancer and other and cervical cancer. However, the prognostic potential of CYFIP2 in pancreatic cancer remains unclear. In this work, we first explain the great potential of CYFIP2 malignant progression from a broader perspective (pan-cancer) and confirm its oncogenic value in pancreatic cancer.  \nMethods The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) database, CELL and GEO databases were utilized to explore the distribution of the CYFIP2 gene in human cancers. Data were analyzed using a variety of web-based platforms and software such as R (4.3.2), UCSC, MethSurv, Cytoscape (v3.10.2), UALAND, STRING, TISIDB, Harmonizome 3.0, TIMER 2.0, TCIA and TIDE. The R packages R packages “limma” and “ggplot2”were used to compare and visualize CYFIP2 mRNA expression. The R packages “survminer” and “survival” were used to statistically analyze the relationship between CYFIP2 expression and the survival and prognosis of tumor patients. the R package “ss GSEA”was used to assess the correlation between CYFIP2 expression and immune infiltration. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Variation Analysis (GSVA) were used to explore the multiple biological functions and regulatory pathways in which CYFIP2 co-expressed genes co-engage in pancreatic cancer. The R package “maftool” was used to explore somatic mutation information in pancreatic cancer, and the TIDE database and the R package “oncoPredic” were used to explore immunotherapeutic responses and sensitive drugs. Pancreatic cancer cell lines were constructed with the specific expression of CYFIP2 mRNA, and their invasive and metastatic abilities were analysed using scratch and transwell assays.  \nResults Bioinformatics analysis and in vitro experiments confirmed that CYFIP2 was differentially expressed in a variety of tumors and correlated with clinical stage, and could be used as a potential marker for evaluating the prognosis and immunotherapy of a variety of tumors, including KIRC (Kidney renal clear cell carcinoma), PAAD (Pancreatic adenocarcinoma), PAAD (Pancreatic adenocarcinoma), SKCM (Skin Cutaneous Melanoma), and UCEC (Uterine Corpus Endometrial Carcinoma).Mutations in the CYFIP2 gene and methylation indices can affect the prognosis of tumor patients. In addition, we found that CYFIP2 expression values in pancreatic cancer were positively correlated with the expression of most immune cells, especially CD8 + T Cells, and significantly negatively correlated with macrophages M0, and negatively correlated with the metastatic and invasive ability of pancreatic cancer cells, which may provide new strategies and ideas for pancreatic cancer immunotherapy.  \nSupplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12672-024-](https://doi.org/10.1007/s12672-024-)[ ](https://doi.org/10.1007/s12672-024-)[01650-5](01650-5.)[.](01650-5.)  \n* Xuefeng Rao, [cong19980208@163.com |](cong19980208@163.com |1Jiangxi Provincial People)[1](cong19980208@163.com |1Jiangxi Provincial People)[Jiangxi Provincial People](cong19980208@163.com |1Jiangxi Provincial People)’s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China. 2The First Affiliated Hospital of Nanchang University, Nanchang University, 17 Yongwai Zhengjie, Donghu District, Nanchang 330006, People’s Republic of China.  \nDiscover Oncology (2024) 15:847 | [https://doi.org/10.1007/s12672-024-01650-5](https://doi.org/1","cbCainu2SjbFd8NQ","https://ap.wps.com/l/cbCainu2SjbFd8NQ","pdf",14959361,21,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Keywords\n## Introduction","[{\"question\":\"What problem does the study address regarding CYFIP2 in pancreatic cancer?\",\"answer\":\"The study addresses the uncertainty about whether CYFIP2 has prognostic potential in pancreatic cancer, despite evidence of CYFIP2 involvement in poor prognosis for other cancers.\"},{\"question\":\"Which databases and analytical tools are used to study CYFIP2?\",\"answer\":\"The study uses TCGA, GTEx, CELL, and GEO, analyzing CYFIP2 distribution, expression, survival relationships, immune infiltration correlation, and pathway functions with multiple web-based platforms and R packages such as limma, ggplot2, survminer, survival, and ssGSEA.\"},{\"question\":\"How is CYFIP2 linked to immune infiltration and tumor progression in the results?\",\"answer\":\"CYFIP2 expression in pancreatic cancer is positively correlated with most immune cells, especially CD8+ T cells, negatively correlated with macrophages M0, and associated with reduced metastatic and invasive ability of pancreatic cancer cells, suggesting a role in immunotherapy strategies.\"}]","CYFIP2 - potential pancreatic cancer biomarker and immunotherapeutic target | PDF",1790024555,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/590cdd33c09507aada34d687188910d6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81a87211171a4c9f79028f6abd468c1a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4557f66ef49efa3bf0fb808517206d59.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10ffba3ff964415eea78c6a95330fdb5.webp",980,1301]